E-Polycaprolactone-Containing Membrane in Alveolar Bone Regeneration (NCT06627621) | Clinical Trial Compass
CompletedEarly Phase 1
E-Polycaprolactone-Containing Membrane in Alveolar Bone Regeneration
Turkey (Türkiye)4 participantsStarted 2021-03-08
Plain-language summary
This study aimed to evaluate the effectiveness of synthetic polycaprolactone (PCL) bioscaffold membranes used for alveolar augmentation in maxillofacial surgery for increasing the amount of newly formed bone after three-dimensional application.
Who can participate
Age range18 Months – 80 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* (1) patients aged \>18 years without any systemic disease or with an established systemic disease that precluded the surgical procedure; (2) patients whose bone deficiency was augmented with PCL scaffolds; (3) patients with an indication for dental implant-supported prosthesis who lacked sufficient bone for dental implants according to cone beam computed tomography (CBCT) evaluation and, therefore, needed bone augmentation; and (4) patients with preoperative and postoperative images.
Exclusion Criteria:
* patients (1) with uncontrolled systemic diseases, (2) who had undergone radiation therapy, (3) who were female and pregnant, (4) who had previously undergone any surgical procedure related to augmentation in the area of the defect, (5) who had incomplete files or lacked pre- and post-treatment radiologic records, or (6) who had psychological problems.
What they're measuring
1
Shapiro-Wilk test
Timeframe: From enrollment to the end of treatment at 6 months